Ophthalmic pharmaceutical composition containing a nitric oxide releasing phosphodiesterase 5 inhibitor and method for producing the same

The ophthalmic composition addresses low solubility and stability issues of NO-PDE5 inhibitors by using surfactants and polyols, achieving a stable, effective, and easily manufactured ophthalmic solution for treating ocular conditions.

JP2024541626APending Publication Date: 2024-11-08NICOX SA
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2024532506
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-02
Filing Date
2022-12-01
Publication Date
2024-11-08

Smart Images

  • Figure 2024541626000001
    Figure 2024541626000001
  • Figure 2024541626000002
    Figure 2024541626000002
  • Figure 2024541626000003
    Figure 2024541626000003
Patent Text Reader

Abstract

The present invention discloses an aqueous ophthalmic formulation in the form of eye drops comprising [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl)methyl 6-(nitrooxy)hexanoate, which can maintain the physical and chemical stability of the active ingredient for a long period of time.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to aqueous ophthalmic formulations in the form of eye drops comprising [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate that are capable of maintaining the physical and chemical stability of the active agent in the dosage form, as well as methods for preparing such ophthalmic formulations. [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate is a nitric oxide releasing phosphodiesterase 5 inhibitor (NO-PDE5 inhibitor), hereinafter referred to as Compound (I). [Background technology]

[0002] Compound (I) is disclosed in WO 2020 / 030489, which relates to NO-releasing PDE5 inhibitors and their use for the treatment of eye diseases involving elevated intraocular pressure, such as ocular hypertension and glaucoma, and for the treatment of retinopathy. WO 2020 / 030489 does not disclose specific pharmaceutical formulations comprising said NO-releasing PDE5 inhibitors. One obstacle in preparing ophthalmic formulations containing Compound (I) in commonly used aqueous ophthalmic vehicles is its rather low aqueous solubility (0.013 mg / ml) and largely lipophilic nature (Clog D pH 6.7 =5.76). In an effort to increase the solubility of Compound (I) in aqueous vehicles, "salt forms" of Compound (I) were investigated. However, in the pH range of 6.0-7.0, which was the initial pH of choice for ophthalmic formulations, the Compound (I) salts tested showed aqueous solubility similar to that of Compound (I) free base. Furthermore, the preparation of the salt requires additional processing steps, increasing the cost of the synthesis; furthermore, the overall yield of the reaction is reduced. Thus, there is a need for aqueous formulations of Compound (I) that contain a therapeutically effective amount of the active ingredient, are easily manufactured, can be stored for long periods under normal handling conditions, and are well tolerated by the eye. Summary of the Invention

[0003] The present invention provides an ophthalmic composition in the form of an aqueous solution comprising the following components: (i) [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate (compound (I)) as the active ingredient; (ii) a surfactant component consisting of a mixture of two non-ionic surfactants selected from the following: macrogol glycerol ricinoleate (Kolliphor® EL), macrogol 40 stearate (Myrj™ S40), and polyoxyethylene sorbitan monooleate (Tween® 80); (iii) a cosolvent selected from polyols which also functions as an osmolality adjuster; (iv) a buffer system to adjust the pH to the range of 4.5 to 7.5; (v) Water for injection or purified water.

[0004] The ophthalmic compositions of the present invention are in the form of eye drops for topical ocular administration. The inventors have found that the combination of surfactant components and the presence of polyols can increase the solubility of Compound (I) in aqueous vehicles, and the resulting clear ophthalmic formulations are generally stable over time without the formation of insoluble precipitates, and furthermore, are well tolerated when tested in animals.

[0005] An embodiment of the present invention comprises: (i) 0.8% to 1.8% w / w of [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate, or any specified value within said range; (ii) a surfactant component selected from the following mixture: - 4.0% to 7.5% w / w Macrogol Glycerol Ricinoleate and 1.0% to 6.0% w / w Macrogol 40 Stearate, - 4.0% to 7.5% w / w macrogolglycerol ricinoleate and 1.0% to 7.0% w / w polyoxyethylene sorbitan monooleate, or -1.0% to 6.0% w / w macrogol 40 stearate and 1.0% to 7.0% w / w polyoxyethylene sorbitan monooleate; (iii) 1.0% to 5.0% w / w of a co-solvent selected from polyols; (iv) a buffer system to adjust the pH to the range of 4.5 to 7.5; (v) Water for injection or purified water (to make 100% w / w); and having an osmolality of 240 to 400 mOsm / kg, preferably 240 to 380 mOsm / kg.

[0006] Another embodiment of the present invention is a method for producing a composition comprising: (i) 1.0% to 1.8% w / w of [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate, or any specified value within said range; (ii) a surfactant component selected from the following mixture: - 5.0% to 7.5% w / w Macrogol Glycerol Ricinoleate and 3.0% to 5.0% w / w Macrogol 40 Stearate, - 5.0% to 7.5% w / w macrogolglycerol ricinoleate and 2.0% to 5.0% w / w polyoxyethylene sorbitan monooleate, or -3.0% to 5.0% w / w macrogol 40 stearate and 2.0% to 5.0% w / w polyoxyethylene sorbitan monooleate; (iii) 1.0% to 4.0% w / w polyethylene glycol 400; (iv) a buffer system to adjust the pH to 4.5-7.5; (v) Water for injection or purified water (to make 100% w / w); and further containing 0.01% to 0.10% w / w EDTA and 0.01% to 0.02% w / w benzalkonium chloride, and having an osmolality of 240 to 400 mOsm / kg, preferably 240 to 380 mOsm / kg.

[0007] An embodiment of the present invention comprises: (i) 1.0% to 1.5% w / w of [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate, or any specified value within said range; (ii) a surfactant component selected from the following mixture: - 5.0% to 7.5% w / w Macrogol Glycerol Ricinoleate and 3.0% to 5.0% w / w Macrogol 40 Stearate, - 5.0% to 7.5% w / w macrogolglycerol ricinoleate and 2.0% to 5.0% w / w polyoxyethylene sorbitan monooleate, or -3.0% to 5.0% w / w macrogol 40 stearate and 2.0% to 5.0% w / w polyoxyethylene sorbitan monooleate; (iii) 1.0% to 4.0% w / w of a co-solvent selected from polyols; (iv) a buffer system to adjust the pH to the range of 4.5 to 7.5; (v) Water for injection or purified water (to make 100% w / w) and having an osmolality of 240 to 400 mOsm / kg, preferably 240 to 380 mOsm / kg.

[0008] In the formulations of the present invention, the polyol co-solvent is preferably selected from mannitol, glycerol, sorbitol or polyethylene glycol; most preferably, the co-solvent is polyethylene glycol 400. In the formulations of the invention, the buffer system is preferably selected from: boric acid and disodium hydrogen phosphate heptahydrate, disodium hydrogen phosphate heptahydrate and sodium dihydrogen phosphate dihydrate, disodium hydrogen phosphate heptahydrate and citric acid, trisodium citrate dihydrate and citric acid monohydrate, trisodium citrate dihydrate and boric acid, or boric acid. More preferably, the buffer system is a mixture of boric acid and disodium hydrogen phosphate heptahydrate or citric acid monohydrate and trisodium citrate dihydrate or trisodium citrate dihydrate and boric acid or boric acid.

[0009] Optionally, the ophthalmic composition further comprises other excipients, such as chelating agents and antimicrobial preservatives. Preferably, the chelating agent is ethylenediaminetetraacetic acid (EDTA), present in the formulation in an amount of 0.01% to 0.2% w / w. Within the terminology of the present invention, EDTA relates to ethylenediaminetetraacetic acid itself as well as to its salts, i.e., for example, the disodium and / or potassium salt.

[0010] The antimicrobial preservative may be selected from benzalkonium chloride (BAK), polyquaternium-1 (PQ-1), quaternary ammonium compounds such as benzethonium chloride, potassium sorbate or sorbic acid, or mixtures thereof, preferably the antimicrobial preservative is benzalkonium chloride. Benzalkonium chloride is N-benzyl-N-(C8-C 18Preferably, the antimicrobial preservative is benzalkonium chloride. The benzalkonium chloride is present in the solution in an amount of 0.01% to 0.02% w / w.

[0011] Optionally, hydrochloric acid and / or sodium hydroxide can be added to the ophthalmic composition to adjust the pH of the final formulation to a pH in the range of 4.5 to 7.5. Other optional excipients that may be included in the ophthalmic formulation are tonicity adjusters such as glycerol, sorbitol, mannitol, dextrose, sodium chloride or potassium chloride, viscosity enhancers such as methylcellulose, hydroxypropylmethylcellulose, antioxidants, or mixtures thereof.

[0012] A preferred embodiment of the present invention comprises: (i) 1.0% w / w [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate; (ii) 5.0% w / w macrogol glycerol ricinoleate and 3.0% w / w macrogol 40 stearate; (iii) 2.8% w / w polyethylene glycol 400; (iv) 0.19% w / w boric acid, 0.51% w / w disodium hydrogen phosphate heptahydrate; (v) Water for injection or purified water (to make 100% w / w); and further containing 0.1% w / w disodium ethylenediaminetetraacetate dihydrate, 0.01% w / w benzalkonium chloride, and HCl or NaOH for adjusting the pH of the final solution to 6.5 to 6.9.

[0013] Another preferred embodiment of the present invention is a process comprising: (i) 1.3% w / w [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate; (ii) 7.5% w / w macrogol glycerol ricinoleate and 5.0% w / w macrogol 40 stearate; (iii) 2.8% w / w polyethylene glycol 400; (iv) 0.19% w / w boric acid, 0.51% w / w disodium hydrogen phosphate heptahydrate; (v) Water for injection or purified water (to make 100% w / w); and further containing 0.1% w / w disodium ethylenediaminetetraacetate dihydrate, 0.01% w / w benzalkonium chloride, and HCl or NaOH for adjusting the pH to 6.5 to 6.9.

[0014] Another preferred embodiment of the present invention is a process comprising: (i) 1.4% w / w [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate; (ii) 7.5% w / w macrogol glycerol ricinoleate and 5.0% w / w macrogol 40 stearate; (iii) 4.0% w / w polyethylene glycol 400; (iv) 0.19% w / w boric acid, 0.51% w / w disodium hydrogen phosphate heptahydrate; (v) Water for injection or purified water (to make 100% w / w); and further containing 0.1% w / w disodium ethylenediaminetetraacetate dihydrate, 0.01% w / w benzalkonium chloride, and HCl or NaOH for adjusting the pH to 6.5 to 6.9.

[0015] Another preferred embodiment of the present invention is a process comprising: (i) 1.8% w / w [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate; (ii) 7.5% w / w macrogolglycerol ricinoleate and 5.0% w / w polyoxyethylene sorbitan monooleate; (iii) 1.0% w / w polyethylene glycol 400; (iv) 0.19% w / w boric acid, 0.51% w / w disodium hydrogen phosphate heptahydrate; (v) Water for injection or purified water (to make 100% w / w); and further containing 0.1% w / w disodium ethylenediaminetetraacetate dihydrate, 0.01% w / w benzalkonium chloride, and HCl or NaOH for adjusting the pH to 6.5 to 6.9.

[0016] Another preferred embodiment of the present invention is a process comprising: (i) 1.7% w / w [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate; (ii) 7.5% w / w macrogolglycerol ricinoleate and 5.0% w / w polyoxyethylene sorbitan monooleate; (iii) 1.0% w / w polyethylene glycol 400; (iv) 0.19% w / w boric acid, 0.51% w / w disodium hydrogen phosphate heptahydrate; (v) Water for injection or purified water (to make 100% w / w); and further containing 0.1% w / w disodium ethylenediaminetetraacetate dihydrate and 0.01% w / w benzalkonium chloride.

[0017] Another preferred embodiment of the present invention is a process comprising: (i) 1.7% w / w [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate; (ii) 7.5% w / w macrogolglycerol ricinoleate and 5.0% w / w polyoxyethylene sorbitan monooleate; (iii) 1.0% w / w polyethylene glycol 400; (iv) 0.11% w / w citric acid monohydrate and 0.73% w / w trisodium citrate dihydrate; (v) Water for injection or purified water (to make 100% w / w); and further containing 0.1% w / w disodium ethylenediaminetetraacetate dihydrate and 0.01% w / w benzalkonium chloride.

[0018] Another preferred embodiment of the present invention is a process comprising: (i) 1.7% w / w [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate; (ii) 7.5% w / w macrogolglycerol ricinoleate and 5.0% w / w polyoxyethylene sorbitan monooleate; (iii) 1.0% w / w polyethylene glycol 400; (iv) 0.19% w / w boric acid, 0.003% w / w trisodium citrate dihydrate; (v) Water for injection or purified water (to make 100% w / w); and further containing 0.1% w / w disodium ethylenediaminetetraacetate dihydrate and 0.01% w / w benzalkonium chloride.

[0019] Another preferred embodiment of the present invention is a process comprising: (i) 1.7% w / w [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate; (ii) 7.5% w / w macrogolglycerol ricinoleate and 5.0% w / w polyoxyethylene sorbitan monooleate; (iii) 1.0% w / w polyethylene glycol 400; (iv) 0.11% w / w citric acid monohydrate, 0.73% w / w trisodium citrate dihydrate; (v) Water for injection or purified water (to make 100% w / w); and further containing 0.1% w / w disodium ethylenediaminetetraacetate dihydrate and 0.01% w / w benzalkonium chloride.

[0020] Another preferred embodiment of the present invention is a process comprising: (i) 1.7% w / w [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate; (ii) 7.5% w / w macrogolglycerol ricinoleate and 5.0% w / w polyoxyethylene sorbitan monooleate; (iii) 1.0% w / w polyethylene glycol 400; (iv) 0.11% w / w citric acid monohydrate, 0.73% w / w trisodium citrate dihydrate; (v) Water for injection or purified water (to make 100% w / w); and further containing 0.1% w / w disodium ethylenediaminetetraacetate dihydrate and 0.01% w / w benzalkonium chloride.

[0021] The percentages of the components of the ophthalmic formulations of the present invention are expressed relative to the total weight of the formulation. Another embodiment of the present invention provides the use of the ophthalmic composition of the present invention to treat glaucoma, ocular hypertension, conditions associated with elevated intraocular pressure, or retinopathy.

[0022] The topical ophthalmic formulations of the present invention can be prepared using a process comprising the steps of: 1) Add the following to a preparation vessel under stirring: Two of the following non-ionic surfactants: macrogol glycerol ricinoleate (Kolliphor EL), macrogol 40 stearate (Myrj S40) and polyoxyethylene sorbitan monooleate (Tween 80), co-solvents, at least 80% by final weight of water for injection or purified water; -Optionally, an antimicrobial preservative, and stirring the mixture to obtain a solution; 2) adding a buffer system, stirring the mixture until completely solubilized, measuring the pH, and optionally adjusting the pH to between 4.5 and 7.5; 3) heating the solution to 65° C., then adding [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate (Compound (I)) and stirring the mixture until Compound (I) is dissolved; 4) cooling the solution to room temperature (RT) under stirring; 5) optionally adding a chelating agent and stirring the mixture to completely solubilize; 6) optionally adjusting the pH value to 4.5-7.5, preferably to pH 6.5-6.9; 7) adjusting the final weight of the solution with water for injection or purified water; 8) checking the pH and adjusting, if necessary, to 4.5 to 7.5, preferably to pH 6.5 to 6.9; 9) Sterile filtering the bulk solution using a suitable filter with a nominal pore size of 0.2 μm or less.

[0023] In particular, the topical ophthalmic formulations of the present invention can be prepared using a process comprising the steps of: 1) Add the following to a preparation vessel under stirring: Two of the following non-ionic surfactants: macrogol glycerol ricinoleate (Kolliphor EL), macrogol 40 stearate (Myrj S40) and polyoxyethylene sorbitan monooleate (Tween 80), cosolvents such as polyethylene glycol 400 (Kollisolv® PEG E 400); - 80% to 90% of the final weight of water for injection or purified water; -Antimicrobial preservatives such as benzalkonium chloride, and stirring the mixture to obtain a solution; 2) adding a buffer system such as boric acid (H3BO3) and disodium hydrogen phosphate heptahydrate (Na2HPO4·7H2O), stirring the mixture until fully solubilized, measuring the pH, and optionally adjusting the pH to between 4.5 and 7.5 with HCl or NaOH; 3) heating the solution to 65° C., then adding [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate (Compound (I)) and stirring the mixture until Compound (I) is dissolved; 4) cooling the solution to room temperature (RT) under stirring; 5) adding a chelating agent such as disodium ethylenediaminetetraacetic acid dihydrate (EDTA) and stirring the mixture to completely solubilize; 6) Optionally, adjusting the pH value to 4.5-7.5, preferably pH 6.5-6.9, with HCl and / or NaOH; 7) adjusting the final weight of the solution with water for injection or purified water; 8) checking the pH and adjusting it to 4.5-7.5, preferably 6.5-6.9, by adding NaOH and / or HCl as necessary; 9) Sterile filtering the bulk solution using a suitable filter with a nominal pore size of 0.2 μm or less. EXAMPLES

[0024] 6-(nitrooxy)hexanoate [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl (compound (I)) was prepared by the synthetic method disclosed in WO 2020 / 030489. Macrogol glycerol ricinoleate (Kolliphor EL), macrogol 40 stearate (Myrj S40), polyoxyethylene sorbitan monooleate (Tween 80) and polyethylene glycol 400 (Kollisolv PEG E 400) are commercially available. Surfactants and cosolvents comply with the requirements of the European and US Pharmacopoeias. The percentages of components in the ophthalmic formulations are expressed relative to the total weight of the formulation (% w / w). "Quantum satis" (qs) means "adding just enough of an ingredient to achieve the desired result." Example 1

[0025] This example illustrates the preparation of an ophthalmic formulation of the invention containing 1.0% w / w of [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate (Compound (I)). 5.0 g of macrogol glycerol ricinoleate (Kolliphor EL), 3.0 g of macrogol 40 stearate (Myrj S40), 2.8 g of polyethylene glycol 400 (Kollisolv PEG 400), 0.01 g of benzalkonium chloride, and 69.9 g of water for injection were weighed into a preparation vessel. The mixture was stirred using a magnetic stir plate until all components were dissolved and the resulting solution appeared slightly yellow or colorless and transparent. 0.19 g of boric acid (H3BO3) and 0.51 g of disodium hydrogen phosphate heptahydrate (Na2HPO47H2O) were added and the mixture was stirred until completely dissolved. The system was then heated to 65°C, followed by the addition of 1 g of compound (I) and stirring for 30 minutes. The solution was then cooled to room temperature (RT) under stirring. 0.10 g of disodium ethylenediaminetetraacetate dihydrate (EDTA) was added and further stirring was performed to obtain a clear solution. The pH of the formulation was then measured and adjusted to 6.5-6.9 by adding aqueous HCl (0.5 M). The remaining water for injection was added to reach a final weight of 100 g and the pH was measured again. The bulk formulation was then filtered under sterile conditions using a suitable filter with a nominal pore size of 0.2 μm. Example 2

[0026] This example illustrates the preparation of an ophthalmic formulation of the invention containing 1.3% w / w of [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate (Compound (I)). 7.5 g of macrogol glycerol ricinoleate (Kolliphor EL), 5.0 g of macrogol 40 stearate (Myrj S40), 2.8 g of polyethylene glycol 400 (Kollisolv PEG 400), 0.01 g of benzalkonium chloride, and 66.1 g of water for injection were weighed into a preparation vessel. The mixture was stirred using a magnetic stir plate until all components were dissolved and the resulting solution appeared slightly yellow or colorless and transparent. 0.19 g of boric acid (H3BO3) and 0.51 g of disodium hydrogen phosphate heptahydrate (Na2HPO4·7H2O) were added and the mixture was stirred until all components were completely dissolved. The system was then heated to 65°C, then 1.3 g of compound (I) was added, followed by stirring for an additional 30 minutes. The solution was then cooled to room temperature (RT) under stirring. 0.10 g of disodium ethylenediaminetetraacetate dihydrate was added and the solution was stirred until completely solubilized. The pH of the resulting formulation was measured and adjusted to 6.5-6.9 by adding aqueous HCl (0.5 M). The remaining water for injection was added to reach a final weight of 100 g, and the pH was measured again. Finally, the bulk formulation was filtered under sterile conditions using a suitable filter with a nominal pore size of 0.2 μm. Example 3

[0027] This example illustrates the preparation of an ophthalmic formulation of the invention containing 1.4% w / w of [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate (Compound (I)). 7.5 g of macrogol glycerol ricinoleate (Kolliphor EL), 5.0 g of macrogol 40 stearate (Myrj S40), 4.0 g of polyethylene glycol 400 (Kollisolv PEG 400), 0.01 g of benzalkonium chloride, and 65.0 g of water for injection were weighed into a preparation vessel. The mixture was stirred using a magnetic stir plate until all components were dissolved and the resulting solution appeared slightly yellow or colorless and transparent. 0.19 g of boric acid (H3BO3) and 0.51 g of disodium hydrogen phosphate heptahydrate (Na2HPO4·7H2O) were added and the mixture was stirred until completely dissolved. The system was then heated to 65°C, then 1.4 g of compound (I) was added and stirred for 30 minutes. The solution was then cooled to room temperature (RT) under stirring. 0.10 g of disodium ethylenediaminetetraacetate dihydrate was added and the solution was stirred until completely solubilized. The pH of the resulting formulation was measured and adjusted to 6.5-6.9 by adding aqueous HCl (0.5 M). The remaining water for injection was added to reach a final weight of 100 g, and the pH was measured again. The bulk formulation was then filtered under sterile conditions using a suitable filter with a nominal pore size of 0.2 μm. Example 4

[0028] This example illustrates the preparation of an ophthalmic formulation of the invention containing 1.8% w / w of [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate (Compound (I)). 7.5 g of macrogolglycerol ricinoleate (Kolliphor EL), 5.0 g of polyoxyethylene sorbitan monooleate (Tween 80), 1.0 g of polyethylene glycol 400 (Kollisolv PEG 400), 0.01 g of benzalkonium chloride, and 67.1 g of water for injection were weighed into a preparation vessel. The mixture was stirred using a magnetic stir plate until all components were dissolved and the resulting solution appeared slightly yellow or colorless and transparent. 0.19 g of boric acid (H3BO3) and 0.51 g of disodium hydrogen phosphate heptahydrate (Na2HPO4·7H2O) were added and the mixture was stirred until completely dissolved. The system was then heated to 65°C, then 1.8 g of compound (I) was added and stirred for 30 minutes. The solution was then cooled to room temperature (RT) under stirring. 0.10 g of disodium ethylenediaminetetraacetate dihydrate was added and the solution was stirred until completely solubilized. The pH of the resulting formulation was measured and adjusted to 6.5-6.9 by adding aqueous HCl (0.5 M). The remaining water for injection was added to reach a final weight of 100 g, and the pH was measured again. The bulk formulation was then filtered under sterile conditions using a suitable filter with a nominal pore size of 0.2 μm. Example 5

[0029] Stability testing of the formulations described in Example 1 The ophthalmic formulation of Example 1 was stored at 25° C. for stability analysis. Samples were analyzed at various time points up to 37 weeks. The results are shown in Table 1. The amount of compound (I) was measured by HPLC equipped with a UV detector using a mixture of two mobile phases (A: 10 mM ammonium acetate adjusted to pH 4.55 by adding 50% acetic acid; B: methanol).

[0030] [Table 1] Example 6

[0031] Stability testing of the formulations described in Example 2 The ophthalmic formulation of Example 2 was stored at 25° C. for stability analysis. Samples were analyzed at various time points up to 8 weeks. The results are shown in Table 2. The amount of compound (I) was measured by HPLC equipped with a UV detector using a mixture of two mobile phases (A: 10 mM ammonium acetate adjusted to pH 4.55 by adding 50% acetic acid; B: methanol).

[0032] [Table 2] Example 7

[0033] Stability testing of the formulations described in Example 3 The ophthalmic formulation of Example 3 was stored at 25° C. for stability analysis. Samples were analyzed at various time points up to 8 weeks. The results are shown in Table 3. The amount of compound (I) was measured by HPLC equipped with a UV detector using a mixture of two mobile phases (A: 10 mM ammonium acetate adjusted to pH 4.55 by adding 50% acetic acid; B: methanol).

[0034] [Table 3] Example 8

[0035] Tolerability study The ophthalmic formulation of Example 1 was tested in non-human primates and also in New Zealand White rabbits. Specifically, the ophthalmic formulation of Example 1 or the corresponding aqueous vehicle (5.0% w / w macrogol glycerol ricinoleate and 3.0% w / w macrogol 40 stearate, 2.8% w / w polyethylene glycol 400, 0.19% w / w boric acid, 0.51% w / w disodium hydrogen phosphate heptahydrate, 0.1% w / w disodium ethylenediaminetetraacetate dihydrate, 0.01% w / w benzalkonium chloride, HCl and water for injection (100% w / w), pH 6.5-6.9) was administered acutely to non-human primates and repeatedly to New Zealand White rabbits twice daily for up to 4 weeks. In all test groups, administration of the ophthalmic formulations, as well as the respective vehicles, did not produce any noticeable signs of discomfort as determined by visual inspection. Example 9

[0036] This example illustrates the preparation of an ophthalmic formulation of the invention containing 1.7% w / w of [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate (Compound (I)). 1.5 g of macrogolglycerol ricinoleate (Kolliphor EL), 1.0 g of polyoxyethylene sorbitan monooleate (Tween 80), 200 mg of polyethylene glycol 400 (Kollisolv PEG E400), 2 mg of benzalkonium chloride, and 13.5 g of water for injection were weighed into a preparation vessel. The mixture was stirred using a magnetic stir plate until a slightly yellow or clear colorless solution was obtained. 38 mg of boric acid (H3BO3) was added and the mixture was stirred until completely dissolved. The mixture was heated to 65°C, then 340 mg of compound (I) was added and the mixture was stirred for 30 minutes. The solution was cooled to room temperature (RT) under stirring, 20 mg of disodium ethylenediaminetetraacetate dihydrate was added and the mixture was stirred until completely solubilized. The pH of the formulation was 5.6. The final weight was adjusted to 20 g by adding water for injection. The resulting mixture was a solution. The bulk solution was then filtered under sterile conditions using a suitable filter with a nominal pore size of 0.2 μm. Example 10

[0037] This example illustrates the preparation of an ophthalmic formulation of the invention containing 1.7% w / w of [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate (Compound (I)). 1.5 g of macrogol glycerol ricinoleate (Kolliphor EL), 1.0 g of polyoxyethylene sorbitan monooleate (Tween 80), 200 mg of polyethylene glycol 400 (Kollisolv PEG E400), 2 mg of benzalkonium chloride, and 13.5 g of water for injection were weighed into a preparation vessel. The mixture was stirred using a magnetic stir plate until a slightly yellow or colorless clear solution was obtained. Citric acid monohydrate (C6H8O7·H2O, 22 mg) and trisodium citrate dihydrate (C6H5Na3O7·2H2O, 146 mg) were added and the mixture was stirred until all components were dissolved. The mixture was heated to 65°C, then 340 mg of compound (I) was added, followed by continuous stirring for 30 minutes. The solution was then cooled to room temperature (RT) under stirring. 20 mg of disodium ethylenediaminetetraacetate dihydrate was added and the solution was stirred to obtain a clear solution. The pH of the formulation was 5.8. The final weight was adjusted to 20 g with water for injection. The resulting mixture was a solution. The resulting bulk solution was finally filtered under sterile conditions using a suitable filter with a nominal pore size of 0.2 μm. Example 11

[0038] This example illustrates the preparation of an ophthalmic formulation of the invention containing 1.7% w / w of [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate (Compound (I)). 1.5 g of macrogolglycerol ricinoleate (Kolliphor EL), 1.0 g of polyoxyethylene sorbitan monooleate (Tween 80), 200 mg of polyethylene glycol 400 (Kollisolv PEG E400), 2 mg of benzalkonium chloride and 13.5 g of water for injection were weighed into a preparation vessel. The mixture was stirred using a magnetic stir plate to obtain a slightly yellow or clear colorless solution. 38 mg of boric acid (H3BO3) and 0.6 mg of trisodium citrate dihydrate (C6H5Na3O7·2H2O) were added and the mixture was stirred until completely dissolved. The mixture was heated to 65°C, 340 mg of compound (I) was added and the resulting mixture was stirred for an additional 30 minutes. The solution was cooled to room temperature (RT) under stirring. 20 mg of disodium ethylenediaminetetraacetate dihydrate was added and the mixture was stirred until all components were completely dissolved. The pH was 5.6. The final weight was adjusted to 20 g with water for injection. The resulting mixture was a solution. The resulting bulk solution was later filtered under sterile conditions using a suitable filter with a nominal pore size of 0.2 μm. Example 12

[0039] This example illustrates the preparation of an ophthalmic formulation of the invention containing 1.7% w / w of [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate (Compound (I)). 750 mg of macrogol glycerol ricinoleate (Kolliphor EL), 500 mg of polyoxyethylene sorbitan monooleate (Tween 80), 100 mg of polyethylene glycol 400 (Kollisolv PEG E 400), 1 mg of benzalkonium chloride, and 6.7 g of water for injection were weighed into a preparation vessel. The mixture was stirred using a magnetic stir plate until a slightly yellow or clear colorless solution was obtained. 11 mg of citric acid monohydrate (C6H8O7·H2O) and 73 mg of trisodium citrate dihydrate (C6H5Na3O7·2H2O) were added and the mixture was stirred until completely dissolved. The pH was adjusted to 5.0 by dropwise addition of 0.5 M HCl. The system was then heated to 65°C, 170 mg of compound (I) was added, and the mixture was stirred for 30 min. The solution was cooled to room temperature (RT) under stirring. 10 mg of disodium ethylenediaminetetraacetate dihydrate was added and the mixture was stirred until completely solubilized. Water for injection was added to adjust the final weight to 10 g. The resulting mixture was a solution. The bulk solution was then filtered under sterile conditions using a suitable filter with a nominal pore size of 0.2 μm. Example 13

[0040] This example illustrates the preparation of an ophthalmic formulation of the invention containing 1.7% w / w of [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate (Compound (I)). 750 mg of macrogol glycerol ricinoleate (Kolliphor EL), 500 mg of polyoxyethylene sorbitan monooleate (Tween 80), 100 mg of polyethylene glycol 400 (Kollisolv PEG E400), 1 mg of benzalkonium chloride and 6.7 g of water for injection were weighed into a preparation vessel. The mixture was stirred using a magnetic stir plate until a slightly yellow or clear colorless solution was obtained. 11 mg of citric acid monohydrate (C6H8O7·H2O) and 73 mg of trisodium citrate dihydrate (C6H5Na3O7·2H2O) were added and the mixture was stirred until completely dissolved. The pH was adjusted to 4.5 by dropwise addition of 0.5 M HCl. The mixture was heated to 65 °C, 170 mg of compound (I) was added and the mixture was stirred for 30 min. The solution was cooled to room temperature (RT) under stirring. 10 mg of disodium ethylenediaminetetraacetate dihydrate was added and the mixture was stirred until completely solubilized. Water for injection was added to adjust the final weight to 10 g. The resulting mixture was a solution. The bulk solution was then filtered under sterile conditions using a suitable filter with a nominal pore size of 0.2 μm. Example 14

[0041] Stability testing of the formulations described in Example 4 The ophthalmic formulation of Example 4 was stored at 25° C. for stability analysis. Samples were analyzed at t0 and 2 weeks. The results are shown in Table 4. The amount of compound (I) was measured by HPLC equipped with a UV detector using a mixture of two mobile phases (A: 10 mM ammonium acetate adjusted to pH 4.55 by adding 50% acetic acid; B: methanol).

[0042] [Table 4] Example 15

[0043] Stability testing of the formulations described in Example 9 The ophthalmic formulation of Example 9 was stored at 25° C. for stability analysis. Samples were analyzed at various time points up to 14 weeks. The results are shown in Table 5. The amount of compound (I) was measured by HPLC equipped with a UV detector using a mixture of two mobile phases (A: 10 mM ammonium acetate adjusted to pH 4.55 by adding 50% acetic acid; B: methanol).

[0044] [Table 5] Example 16

[0045] Stability testing of the formulations described in Example 10 The ophthalmic formulation of Example 10 was stored at 25° C. for stability analysis. Samples were analyzed at various time points up to 8 weeks. The results are shown in Table 6. The amount of compound (I) was measured by HPLC equipped with a UV detector using a mixture of two mobile phases (A: 10 mM ammonium acetate adjusted to pH 4.55 by adding 50% acetic acid; B: methanol).

[0046] [Table 6] Example 17

[0047] Stability testing of the formulations described in Example 11 The ophthalmic formulation of Example 11 was stored at 25° C. for stability analysis. Samples were analyzed at various time points up to 8 weeks. The results are shown in Table 7. The amount of compound (I) was measured by HPLC equipped with a UV detector using a mixture of two mobile phases (A: 10 mM ammonium acetate adjusted to pH 4.55 by adding 50% acetic acid; B: methanol).

[0048] [Table 7] Example 18

[0049] Stability testing of the formulations described in Example 12 The ophthalmic formulation of Example 12 was stored at 25° C. for stability analysis. Samples were analyzed at various time points up to 15 weeks. The results are shown in Table 8. The amount of compound (I) was measured by HPLC equipped with a UV detector using a mixture of two mobile phases (A: 10 mM ammonium acetate adjusted to pH 4.55 by adding 50% acetic acid; B: methanol).

[0050] [Table 8] Example 19

[0051] Stability testing of the formulations described in Example 13 The ophthalmic formulation of Example 13 was stored at 25° C. for stability analysis. Samples were analyzed at various time points up to 15 weeks. The results are shown in Table 9. The amount of compound (I) was measured by HPLC equipped with a UV detector using a mixture of two mobile phases (A: 10 mM ammonium acetate adjusted to pH 4.55 by adding 50% acetic acid; B: methanol).

[0052] [Table 9]

[0053] The stability data reported in Tables 1-9 demonstrate that the formulations of the present invention are chemically and physically stable at room temperature conditions and therefore do not require refrigerated storage conditions, thereby facilitating an easy drug supply chain and improving patient compliance with drug storage recommendations.

[0054] Comparative Example The following examples disclose the preparation of ophthalmic formulations containing [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate (Compound (I)), and the vehicles of the ophthalmic formulations of Comparative Examples 20-24 contain the same "surfactant component" and co-solvent as the formulations of the present invention, but the amounts of "surfactant component" and co-solvent are less than those of the present invention. The ophthalmic formulations of Comparative Examples 25 and 26 contain surfactant only at concentrations within the range of the present invention, but the concentration of co-solvent is higher than that of the formulations of the present invention. Comparative Example formulations were prepared by adding 1% w / w of Compound (I) (Examples 20-23 and 25) or 1.5% w / w of Compound (I) (Examples 24 and 25) and evaluated at the end of the preparation for the macroscopic appearance of the formulation and the amount of Compound (I) dissolved in the formulation vehicle. Example 20

[0055] 350 g of macrogol glycerol ricinoleate (Kolliphor EL), 50 mg of macrogol stearate 40 (Myrj S40), 50 mg of polyethylene glycol 400 (Kollisolv PEG E 400), 1 mg of benzalkonium chloride and 9.3 g of water for injection were weighed into a preparation vessel. The mixture was stirred using a magnetic stir plate until a slightly yellow or colorless solution was obtained. 19 mg of boric acid (H3BO3) and 51 mg of disodium hydrogen phosphate heptahydrate (Na2HPO4·7H2O) were added and the mixture was stirred until completely dissolved. The solution was heated to 65°C, then 100 mg of compound (I) was added and the mixture was stirred for 30 minutes. The mixture was cooled to room temperature (RT) under stirring. 10 mg of disodium ethylenediaminetetraacetate dihydrate (EDTA) was added and the mixture was stirred for 10 minutes. The final weight was adjusted to 10 g by adding water for injection. The pH was 7.6. The resulting mixture was a suspension. The suspension was centrifuged and the amount of Compound (I) in the supernatant solution (vehicle) was quantified by HPLC against a calibration curve. The formulation was stored at RT, and 31 weeks after preparation, a sample of the suspension was centrifuged and the amount of Compound (I) in the supernatant solution was quantified by HPLC against a calibration curve. The results of the two analyses are shown in the following table (Table 10).

[0056] [Table 10] Example 21

[0057] 350 mg of macrogol glycerol ricinoleate (Kolliphor EL), 50 mg of polyoxyethylene sorbitan monooleate (Tween 80), 50 mg of polyethylene glycol 400 (Kollisolv PEG E400), 1 mg of benzalkonium chloride and 9.3 g of water for injection were weighed into a preparation vessel. The mixture was stirred using a magnetic stir plate until a slightly yellow or colorless solution was obtained. 19 mg of boric acid (H3BO3) and 51 mg of disodium hydrogen phosphate heptahydrate (Na2HPO4·7H2O) were added and the mixture was stirred until completely dissolved. The solution was heated to 65°C, then 100 mg of compound (I) was added and the mixture was stirred for 30 minutes. The mixture was cooled to room temperature (RT) under stirring. 10 mg of disodium ethylenediaminetetraacetate dihydrate (EDTA) was added and the mixture was stirred for 10 minutes. The final weight was adjusted to 10 g by adding water for injection. The pH was 7.6. The resulting mixture was a suspension. The suspension was centrifuged, and the amount of Compound (I) in the supernatant solution (vehicle) was quantified by HPLC against a calibration curve. The formulation was stored at RT, and 30 weeks after preparation, a sample of the suspension was centrifuged, and the amount of Compound (I) in the supernatant solution was quantified by HPLC against a calibration curve. The results of the two analyses are shown in the following table (Table 11).

[0058] [Table 11] Example 22

[0059] 350 mg of macrogol glycerol ricinoleate (Kolliphor EL), 50 mg of macrogol stearate 40 (Myrj S40), 50 mg of polyethylene glycol 400 (Kollisolv PEG E400), 1 mg of benzalkonium chloride and 9 g of water for injection were weighed into a preparation vessel. The mixture was stirred using a magnetic stir plate until a slightly yellow or colorless solution was obtained. 19 mg of boric acid (H3BO3) and 51 mg of disodium hydrogen phosphate heptahydrate (Na2HPO4·7H2O) were added and the mixture was stirred until completely dissolved. The pH was adjusted to 3.1-4.2 by adding 0.5 M HCl. The solution was heated to 65 °C, then 100 mg of compound (I) was added and the mixture was stirred for 30 min. The mixture was cooled to room temperature (RT) under stirring. 10 mg of disodium ethylenediaminetetraacetate dihydrate (EDTA) was added and the mixture was stirred for 1 h. The final weight was adjusted to 10 g with water for injection. The pH was 4.2. The resulting mixture was a suspension. The suspension was centrifuged, and the amount of Compound (I) in the supernatant solution (vehicle) was quantified by HPLC against a calibration curve. The formulation was stored at RT, and 27 weeks after preparation, a sample of the suspension was centrifuged, and the amount of Compound (I) in the supernatant solution was quantified by HPLC against a calibration curve. The results of the two analyses are shown in the following table (Table 12).

[0060] [Table 12] Example 23

[0061] 350 mg of macrogol glycerol ricinoleate (Kolliphor EL), 50 mg of polyoxyethylene sorbitan monooleate (Tween 80), 50 mg of polyethylene glycol 400 (Kollisolv PEG E 400), 1 mg of benzalkonium chloride and 9 g of water for injection were weighed into a preparation vessel. The mixture was stirred using a magnetic stir plate until a slightly yellow or colorless solution was obtained. 19 mg of boric acid (H3BO3) and 51 mg of disodium hydrogen phosphate heptahydrate (Na2HPO4·7H2O) were added and the mixture was stirred until completely dissolved. The pH was adjusted to 3.1-4.2 by dropwise addition of 0.5 M HCl. The solution was heated to 65 °C, then 100 mg of compound (I) was added and the mixture was stirred for 30 min. The mixture was cooled to room temperature (RT) under stirring. 10 mg of disodium ethylenediaminetetraacetate dihydrate (EDTA) was added and the mixture was stirred for 1 h. The final weight was adjusted to 10 g with water for injection. The pH was 4.2. The resulting mixture was a suspension. The suspension was centrifuged, and the amount of Compound (I) in the supernatant solution (vehicle) was quantified by HPLC against a calibration curve. The formulation was stored at RT, and 27 weeks after preparation, a sample of the suspension was centrifuged, and the amount of Compound (I) in the supernatant solution was quantified by HPLC against a calibration curve. The results of the two analyses are shown in the following table (Table 13).

[0062] [Table 13] Example 24

[0063] 350 mg macrogol glycerol ricinoleate (Kolliphor EL), 50 mg macrogol stearate 40 (Myrj S40), 550 mg polyethylene glycol 400 (Kollisolv PEG E 400), 1 mg benzalkonium chloride and 8 g water for injection were weighed into a preparation vessel. The mixture was stirred using a magnetic stir plate until a slightly yellow or colorless solution was obtained. 19 mg boric acid (H3BO3) and 51 mg disodium hydrogen phosphate heptahydrate (Na2HPO4·7H2O) were added and the mixture was stirred until completely dissolved. The solution was heated to 65°C, then 150 mg compound (I) was added and the mixture was stirred for 30 minutes. The mixture was cooled to room temperature (RT) under stirring, 10 mg disodium ethylenediaminetetraacetate dihydrate (EDTA) was added and the mixture was stirred for 20 minutes. The final weight was adjusted to 10 g by adding water for injection. The pH was 7.6. The resulting mixture was a suspension. The suspension was centrifuged, and the amount of Compound (I) in the supernatant solution (vehicle) was quantified by HPLC against a calibration curve. The formulation was stored at RT, and two weeks after preparation, an aliquot was taken, centrifuged, and the amount of Compound (I) in the supernatant solution was quantified by HPLC against a calibration curve. The results of two independent analyses are shown in the following table (Table 14).

[0064] [Table 14] Example 25

[0065] 650 mg of macrogol 40 stearate (Myrj S40), 50 mg of polyethylene glycol 400 (Kollisolv PEG E400), 1 mg of benzalkonium chloride and 9.1 g of water for injection were weighed into a preparation vessel. The mixture was stirred using a magnetic stir plate until a slightly yellow or colorless solution was obtained. 19 mg of boric acid (H3BO3) and 51 mg of disodium hydrogen phosphate heptahydrate (Na2HPO4·7H2O) were added and the mixture was stirred until completely dissolved. The solution was heated to 65°C, then 100 mg of compound (I) was added and the mixture was stirred for an additional 30 minutes. The mixture was cooled to room temperature (RT) under stirring and 10 mg of disodium ethylenediaminetetraacetate dihydrate (EDTA) was added with stirring for an additional 10 minutes. The final weight was adjusted to 10 g by adding water for injection. The pH was 7.6. The resulting mixture was a suspension. The suspension was centrifuged, and the amount of Compound (I) in the supernatant solution (vehicle) was quantified by HPLC against a calibration curve. The formulation was stored at RT, and 30 weeks after preparation, an aliquot was taken, centrifuged, and the amount of Compound (I) was quantified by HPLC against a calibration curve. The results of the two independent analyses are shown in the following table (Table 15).

[0066] [Table 15] Example 26

[0067] 650 mg of macrogol 40 stearate (Myrj S40), 550 mg of polyethylene glycol 400 (Kollisolv PEG E400), 1 mg of benzalkonium chloride and 8.5 g of water for injection were weighed into a preparation vessel. The mixture was stirred using a magnetic stir plate until a slightly yellow or colorless solution was obtained. 19 mg of boric acid (H3BO3) and 51 mg of disodium hydrogen phosphate heptahydrate (Na2HPO4·7H2O) were added and the mixture was stirred until completely dissolved. The solution was heated to 65°C, then 150 mg of compound (I) was added and the mixture was stirred for 30 minutes. The mixture was cooled to room temperature (RT) under stirring. 10 mg of disodium ethylenediaminetetraacetate dihydrate (EDTA) was added and the mixture was stirred for 20 minutes. The final weight was adjusted to 10 g by adding water for injection. The pH was 7.6. The resulting mixture was a suspension. The suspension was centrifuged, and the amount of Compound (I) in the supernatant solution (vehicle) was quantified by HPLC against a calibration curve. The formulation was stored at RT, and two weeks after preparation, a sample of the suspension was centrifuged, and the amount of Compound (I) in the supernatant solution was quantified by HPLC against a calibration curve. The results of the two analyses are shown in the following table (Table 16).

[0068] [Table 16]

[0069] comment The comparative example formulations contain the same surfactant components and co-solvents as the formulations of the invention, but at lower concentrations (see Examples 20-24), or other formulations contain surfactants and co-solvents at higher concentrations than in the formulations of the invention (Examples 25 and 26). All of the comparative example formulations were suspensions. Analysis of the comparative example formulations showed that the concentration of compound (I) in the supernatant solution of the formulations of Examples 20, 21, 24 to 26 was less than 0.8%. At lower pH (pH 4.2), the concentration of compound (I) increased to 0.8%, but pH had an effect on the degradation of the active ingredient, i.e., after 27 weeks of storage, a decrease in purity of about 8 to 10% was observed (see Examples 22 and 23). A summary of the stability analysis of Comparative Examples 20-26 and Example 1 for ophthalmic formulations of the invention containing 1% w / w of Compound (I) of the invention is shown in Table 17.

[0070] [Table 17]

Claims

1. (i) 0.8% to 1.8% w / w of [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate, or any specific value within said range; (ii) a surfactant component selected from the following mixture: - 4.0% to 7.5% w / w Macrogol Glycerol Ricinoleate and 1.0% to 6.0% w / w Macrogol 40 Stearate, - 4.0% to 7.5% w / w macrogolglycerol ricinoleate and 1.0% to 7.0% w / w polyoxyethylenesorbitan monooleate, or - 1.0% to 6.0% w / w macrogol 40 stearate and 1.0% to 7.0% w / w polyoxyethylene sorbitan monooleate; (iii) 1.0% to 5.0% w / w of a co-solvent selected from polyols; (iv) a buffer system to adjust the pH to a range of 4.5 to 7.5; (v) Water for injection or purified water (to make 100% w / w); and having an osmolality of 240 to 400 mOsm / kg, preferably 240 to 380 mOsm / kg.

2. (i) 1.0% to 1.8% w / w of [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate, or any specific value within said range; (ii) a surfactant component selected from the following mixture: - 5.0% to 7.5% w / w Macrogol Glycerol Ricinoleate and 3.0% to 5.0% w / w Macrogol 40 Stearate, - 5.0% to 7.5% w / w macrogolglycerol ricinoleate and 2.0% to 5.0% w / w polyoxyethylenesorbitan monooleate, or - 3.0% to 5.0% w / w macrogol 40 stearate and 2.0% to 5.0% w / w polyoxyethylene sorbitan monooleate; (iii) 1.0% to 4.0% w / w polyethylene glycol 400; (iv) a buffer system to adjust the pH to between 4.5 and 7.5; (v) Water for injection or purified water (to make 100% w / w); and further comprising 0.01% to 0.10% w / w EDTA and 0.01% to 0.02% w / w benzalkonium chloride.

3. (i) 1.0% to 1.5% w / w of [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate, or any specific value within said range; (ii) a surfactant component selected from the following mixture: - 5.0% to 7.5% w / w Macrogol Glycerol Ricinoleate and 3.0% to 5.0% w / w Macrogol 40 Stearate, - 5.0% to 7.5% w / w macrogolglycerol ricinoleate and 2.0% to 5.0% w / w polyoxyethylene sorbitan monooleate, or - 3.0% to 5.0% w / w macrogol 40 stearate and 2.0% to 5.0% w / w polyoxyethylene sorbitan monooleate; (iii) 1.0% to 4.0% w / w of a co-solvent selected from polyols; (iv) a buffer system to adjust the pH to a range of 4.5 to 7.5; (v) Water for injection or purified water (to make 100% w / w) 2. The ophthalmic formulation of claim 1, comprising:

4. The ophthalmic formulation according to any one of claims 1 to 3, wherein the co-solvent is selected from mannitol, glycerol, sorbitol or polyethylene glycol.

5. The ophthalmic formulation of any one of claims 1 to 3, wherein the co-solvent is polyethylene glycol 400.

6. 6. The ophthalmic formulation of any one of claims 1 to 5, wherein the buffer system is selected from the following: boric acid and disodium hydrogen phosphate heptahydrate, disodium hydrogen phosphate heptahydrate and sodium dihydrogen phosphate dihydrate, disodium hydrogen phosphate heptahydrate and citric acid, trisodium citrate dihydrate and citric acid monohydrate, trisodium citrate dihydrate and boric acid, or boric acid.

7. 7. The ophthalmic preparation according to any one of claims 1 to 6, wherein the buffer system is selected from boric acid and disodium hydrogen phosphate heptahydrate or citric acid monohydrate and trisodium citrate dihydrate or trisodium citrate dihydrate and boric acid or boric acid.

8. The ophthalmic composition according to any one of claims 1 to 7, further comprising a chelating agent.

9. 9. The ophthalmic preparation of claim 8, wherein the chelating agent is 0.01% to 0.2% w / w ethylenediaminetetraacetic acid or a salt thereof.

10. 10. The ophthalmic formulation of any one of claims 1 to 9, further comprising an antimicrobial preservative selected from benzalkonium chloride, polyquaternium-1, benzethonium chloride, potassium sorbate or sorbic acid, or mixtures thereof.

11. 11. The ophthalmic formulation of claim 10, wherein the antimicrobial preservative is benzalkonium chloride.

12. 12. The ophthalmic formulation of any one of claims 1 to 11, further comprising one or more tonicity adjusting agents selected from glycerol, sorbitol, mannitol, dextrose, sodium chloride or potassium chloride.

13. The ophthalmic formulation according to any one of claims 1 to 12, further comprising a viscosity enhancing agent selected from methylcellulose, hydroxypropylmethylcellulose, an antioxidant or a mixture thereof.

14. (i) 1.0% w / w [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate; (ii) 5.0% w / w macrogol glycerol ricinoleate and 3.0% w / w macrogol 40 stearate; (iii) 2.8% w / w polyethylene glycol 400; (iv) 0.19% w / w boric acid, 0.51% w / w disodium hydrogen phosphate heptahydrate; (v) Water for injection (qs) (to make 100% w / w); 2. The ophthalmic formulation of claim 1, further comprising 0.1% w / w disodium ethylenediaminetetraacetate dihydrate, 0.01% w / w benzalkonium chloride, and HCl or NaOH to adjust the pH to 6.5-6.

9.

15. (i) 1.3% w / w [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate; (ii) 7.5% w / w macrogol glycerol ricinoleate and 5.0% w / w macrogol 40 stearate; (iii) 2.8% w / w polyethylene glycol 400; (iv) 0.19% w / w boric acid, 0.51% w / w disodium hydrogen phosphate heptahydrate; (v) Water for injection (qs) (to make 100% w / w); and further comprising 0.1% w / w disodium ethylenediaminetetraacetate dihydrate, 0.01% w / w benzalkonium chloride, and HCl or NaOH to adjust the pH to 6.5-6.

9.

16. (i) 1.4% w / w [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate; (ii) 7.5% w / w macrogol glycerol ricinoleate and 5.0% w / w macrogol 40 stearate; (iii) 4.0% w / w polyethylene glycol 400; (iv) 0.19% w / w boric acid, 0.51% w / w disodium hydrogen phosphate heptahydrate; (v) Water for injection (qs) (to make 100% w / w); 2. The ophthalmic formulation of claim 1, further comprising 0.1% w / w disodium ethylenediaminetetraacetate dihydrate, 0.01% w / w benzalkonium chloride, and HCl to adjust the pH to 6.5-6.

9.

17. (i) 1.8% w / w [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate; (ii) 7.5% w / w macrogolglycerol ricinoleate and 5.0% w / w polyoxyethylene sorbitan monooleate; (iii) 1.0% w / w polyethylene glycol 400; (iv) 0.19% w / w boric acid, 0.51% w / w disodium hydrogen phosphate heptahydrate; (v) Water for injection (qs) (to make 100% w / w); and further comprising 0.1% w / w disodium ethylenediaminetetraacetate dihydrate, 0.01% w / w benzalkonium chloride, and HCl or NaOH to adjust the pH to 6.5-6.

9.

18. (i) 1.7% w / w [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate; (ii) 7.5% w / w macrogolglycerol ricinoleate and 5.0% w / w polyoxyethylene sorbitan monooleate; (iii) 1.0% w / w polyethylene glycol 400; (iv) 0.19% w / w boric acid, 0.51% w / w disodium hydrogen phosphate heptahydrate; (v) Water for injection or purified water (to make 100% w / w); 2. The ophthalmic formulation of claim 1, further comprising 0.1% w / w disodium ethylenediaminetetraacetate dihydrate, 0.01% w / w benzalkonium chloride.

19. (i) 1.7% w / w [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate; (ii) 7.5% w / w macrogolglycerol ricinoleate and 5.0% w / w polyoxyethylene sorbitan monooleate; (iii) 1.0% w / w polyethylene glycol 400; (iv) 0.11% w / w citric acid monohydrate and 0.73% w / w trisodium citrate dihydrate; (v) Water for injection or purified water (to make 100% w / w); 2. The ophthalmic formulation of claim 1, further comprising 0.1% w / w disodium ethylenediaminetetraacetate dihydrate, 0.01% w / w benzalkonium chloride.

20. (i) 1.7% w / w [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate; (ii) 7.5% w / w macrogolglycerol ricinoleate and 5.0% w / w polyoxyethylene sorbitan monooleate; (iii) 1.0% w / w polyethylene glycol 400; (iv) 0.19% w / w boric acid, 0.003% w / w trisodium citrate dihydrate; (v) Water for injection or purified water (to make 100% w / w); 2. The ophthalmic formulation of claim 1, further comprising 0.1% w / w disodium ethylenediaminetetraacetate dihydrate, 0.01% w / w benzalkonium chloride.

21. (i) 1.7% w / w [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate; (ii) 7.5% w / w macrogolglycerol ricinoleate and 5.0% w / w polyoxyethylene sorbitan monooleate; (iii) 1.0% w / w polyethylene glycol 400; (iv) 0.11% w / w citric acid monohydrate, 0.73% w / w trisodium citrate dihydrate; (v) Water for injection or purified water (to make 100% w / w); 2. The ophthalmic formulation of claim 1, further comprising 0.1% w / w disodium ethylenediaminetetraacetate dihydrate, 0.01% w / w benzalkonium chloride.

22. (i) 1.7% w / w [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate; (ii) 7.5% w / w macrogolglycerol ricinoleate and 5.0% w / w polyoxyethylene sorbitan monooleate; (iii) 1.0% w / w polyethylene glycol 400; (iv) 0.11% w / w citric acid monohydrate, 0.73% w / w trisodium citrate dihydrate; (v) Water for injection or purified water (to make 100% w / w); 2. The ophthalmic formulation of claim 1, further comprising 0.1% w / w disodium ethylenediaminetetraacetate dihydrate, 0.01% w / w benzalkonium chloride.

23. 20. An ophthalmic formulation according to any one of claims 1 to 19 for use in treating glaucoma, ocular hypertension, conditions associated with elevated intraocular pressure or retinopathy.

Citation Information

Patent Citations

  • Artificial tears, contact lenses and drug carrier compositions and methods of use thereof

    JP2019535657A

  • Compositions and methods for treating dry eye disease

    JP2020511445A

  • Process for preparing pharmaceutical ophthalmic compositions of brinzolamide

    WO2018001445A1

  • Nitric oxide releasing phosphodiesterase type 5 inhibitor

    WO2020030489A1

  • Compositions for the treatment of glaucoma and ocular hypertension

    WO2021156275A1